Journal of Clinical and Aesthetic Dermatology最新文献

{"title":"Efficacy and Safety of Microencapsulated Benzoyl Peroxide Cream, 5%, in Papulopustular Rosacea in Elderly Patients: Post-hoc Analysis of Results from Two Randomized, Phase III, Vehicle-controlled Trials.","authors":"Lawrence J Green, Hilary Baldwin, Jeffrey Sugarman, Bill Andriopoulos, Ori Nov, Ofra Levy-Hacham, Neal Bhatia, William P Werschler","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>We sought to compare the efficacy and safety of encapsulated benzoyl peroxide (E-BPO) cream, 5%, versus vehicle in subjects <65 years of age versus subjects ≥65 with moderate to severe papulopustular rosacea.</p><p><strong>Methods: </strong>This analysis used pooled results from two 12-week, randomized, vehicle-controlled Phase III trials (NCT03564119, NCT03448939) of E-BPO cream, 5%. These trials included 733 subjects randomized 2:1 to E-BPO or vehicle. The primary endpoints were success in the Investigator's Global Assessment (IGA) score and reduction in mean inflammatory lesion count at Week 12.</p><p><strong>Results: </strong>Our analysis shows that E-BPO cream, 5%, was significantly superior to vehicle in achieving IGA success and reducing inflammatory lesions in both age groups. IGA success was achieved in 48.3% of subjects who received E-BPO versus 25.4% for vehicle in the intent-to-treat population. The E-BPO and vehicle IGA success percentages for subjects <65 were 45.7% and 23.8%, respectively, and those for subjects ≥65 were 60.0% and 28.1%, respectively. The absolute reduction from baseline in inflammatory lesions was -19.3 for subjects who received E-BPO versus -11.4 for those who received vehicle. The E-BPO and vehicle absolute reduction values for subjects <65 were -19.6 and -11.2, respectively, and 17.5 and -10.4 for subjects ≥65. There were no significant differences in the frequencies of adverse events or cutaneous tolerability.</p><p><strong>Limitations: </strong>E-BPO was not compared to nonencapsulated BPO.</p><p><strong>Conclusion: </strong>This combined analysis of results from the two Phase III, randomized, double-blind controlled studies of E-BPO cream, 5%, showed it was efficacious, tolerable, and safe, regardless of age.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 10","pages":"41-44"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11495165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142512829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of Vascular Anomalies in Patients with Skin of Color.","authors":"Marta E Taye, Jay Shah, Elizabeth V Seiverling, Leslie P Lawley","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Vascular anomalies can be broadly classified as vascular tumors or vascular malformations, depending on the degree of endothelial involvement. These lesions can be subtle and challenging to diagnose in individuals with darker skin tones, which can lead to a delay in treatment. Improving diagnostic accuracy of these lesions may prevent progression and potential adverse outcomes when left untreated. Here, we present a review of common vascular anomalies with a focus on diagnostic considerations in individuals with skin of color.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 10","pages":"54-62"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11495159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142512826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carboxytherapy versus its Combination with Fractional CO₂ Laser for the Treatment of Striae Distensae: An Objective, Right-to-left, Comparative Study.","authors":"Moetaz El-Domyati, Wael Hosam El-Din, Walid Medhat, Yasmin Khaled, Michel R Ibrahim","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Striae distensae (SD) is a common cutaneous disorder which appears as linear lesions seen mainly in women. Since previously described in 1889, SD has presented a significant challenge regarding its evaluation and treatment. Carboxytherapy was recently reported as an effective treatment for SD.</p><p><strong>Objectives: </strong>We sought to objectively compare the clinical effectiveness of carbon dioxide therapy (CDT) as monotherapy versus a combination of CDT and fractional CO₂ laser in the treatment of SD.</p><p><strong>Methods: </strong>This randomized prospective study included twenty cases with bilateral and symmetrical SD. Each patient was treated with CDT only on the right (Rt) side of the body, while the left (Lt) side received a combination of CDT and fractional C0₂ laser.</p><p><strong>Results: </strong>Clinical evaluation revealed a clearly significant clinical improvement in SD lesions after both techniques regarding length, width, texture, and pigment changes. Although the Lt side showed slightly better improvement, however no statistically significant difference could be observed between both sides. In the meantime, the objective improvement observed by the 3D camera and histometric analysis correlated with the clinical improvement. Special stains showed collagen deposition which became more compact, dense and better organized, accompanied by evident increase in elastic fibers in a normal linear microfibrillar pattern after treatment on both sides.</p><p><strong>Conclusion: </strong>CDT demonstrated efficacy and safety as a minimally invasive modality for management of SD, as it induces collagen remodeling and better organization of elastic fibers with minimal side effects and downtime.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 10","pages":"E69-E75"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11495166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142512825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in Basal Cell Carcinoma: A Comparative Analysis of Hispanic and Non-Hispanic White Individuals.","authors":"Miguel A Aristizabal, Daniel Zieman, Hannah S Berman, Kyle A Williams, Dane J Markham, Michael G Heckman, Alex Hochwald, Naiara S Barbosa, Catherine Degesys","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>We sought to examine possible differences in BCC characteristics and treatment patterns between two matched cohorts of Hispanic White and non-Hispanic White individuals.</p><p><strong>Methods: </strong>In this single institution, retrospective matched cohort study, data from patients with biopsy proven BCC from June 2005 to May 2022 was collected. Demographic, BCC, and treatment characteristics were compared between Hispanic White and non-Hispanic White individuals using a Wilcoxon rank-sum test, for continuous and ordinal variables, and Fisher's exact test, for categorical variables.</p><p><strong>Results: </strong>A total of 604 individuals with a diagnosis of biopsy-proven BCC were matched in a 1:1 fashion by age (± 0 years) and sex, based on self-identified ethnicity as Hispanic or non-Hispanic. Since all patients self-identified as White race, the two cohorts were labeled Hispanic White (n=302) and non-Hispanic White (n=302). The most frequent location for BCC was in the H area, 129 [42.7%] White Hispanic group vs 132 [43.7%] White non-Hispanic group (p = 0.87). In both Hispanic White and non-Hispanic White groups, the predominant subtype of BCC was the nodular (149 [50.2%] vs 164 [54.7%], p = 0.25). The median BCC pre-operative size in the Hispanic White group was 0.9 cm, whereas in the non-Hispanic White group, it was 1.0 cm (p = 0.004). Furthermore, the MMS defect size in the Hispanic White group had a median of 1.3 cm, while in the non-Hispanic White group, it was 1.6 cm (p < 0.001).</p><p><strong>Limitations: </strong>Retrospective design, single-center study, and self-reported race and ethnicity.</p><p><strong>Conclusion: </strong>Both groups had similar demographics, tumor features, treatments, and post-operative complications. Notably, preoperative lesion and MMS defect sizes were larger in non-Hispanic Whites than in Hispanic Whites, contrary to expectations. Despite assumptions of poorer skin cancer outcomes among Hispanics, our findings indicate increased sizes in non-Hispanic Whites. Given the diversity in genetics and clinical traits within ethnicities, especially Hispanics, more research is needed for precise insights into disease outcomes across diverse backgrounds.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 10","pages":"24-27"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11495162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142512828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significantly Enhanced Improvement in Dryness, Roughness, Fine Lines and Radiance Following Daily Use of a Novel Multi-Weight Hyaluronic Acid Plus Antioxidant Complex-Based Lotion Compared to a Single-Weight HA Plus Ceramide-Based Lotion.","authors":"Kavita Mariwalla, Joshua Zeichner, Michael Folsom-Kovarik, Omid Yousefian, Craig Arrowitz, Edward Lain","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Hyaluronic acid (HA) has become a commonly used ingredient in topical moisturizing products; however, limitations of delivery of HA to only the surface of skin have hindered leveraging the full capacity of HA for skin rejuvenation. Here, we aimed to evaluate the clinical benefits of a multi-weight HA plus antioxidant complex-based lotion with SPF 30 compared to a single-weight HA plus ceramide-based lotion with SPF 30.</p><p><strong>Methods: </strong>A double-blind comparative study was conducted on 70 female subjects, aged 25 to 65 years with mild-to-moderate facial dryness and visible fine lines and wrinkles, divided evenly into two groups (n=35 per group). Clinical grading of the face, including dryness, roughness, and fine lines, was assessed after once-daily application for up to eight weeks.</p><p><strong>Results: </strong>Daily use of the multi-weight HA plus antioxidant lotion demonstrated significant improvements in all clinical grading assessments (dryness, roughness, and fine lines) as early as Week 2 compared to baseline. Statistically significant improvements in visible dryness, roughness, and fine lines were greater for the multi-weight HA plus antioxidant lotion compared to the single-weight HA plus ceramide-based lotion.</p><p><strong>Limitations: </strong>The overall small sample size.</p><p><strong>Conclusion: </strong>This study showed the enhanced improvement in dryness, roughness, and fine lines following daily utilization of a novel multi-weight HA plus antioxidant complex-based lotion compared to a single-weight HA plus ceramide-based lotion. These improvements may be attributed to the ability of multi-weight HAs to moisturize the skin surface and penetrate the upper surface layers of the skin, combined with the added benefits of key antioxidants.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 9","pages":"44-47"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11386971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Acne the Same Around the World?","authors":"Andrew Alexis, Jerry Tan, Marco Rocha, Delphine Kerob, Ann'Laure Demessant, Fatimata Ly, Yan Wu, Mukta Sachdev, Ichiro Kurokawa","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Acne is a common skin disease associated with a range of sequelae. These include scarring and dyspigmentation, emotional and psychosocial disturbances, and occupational problems, in part because acne often manifests on the face, in addition to other body areas, and is highly visible. Worldwide, the prevalence of acne is estimated at 9.4 percent; it is most common in adolescents but also affects a relatively high proportion of adults. Early studies of acne epidemiology were conducted primarily in the United States and the United Kingdom. In more recent decades, data have been increasing for other areas of the world. There has also been more attention devoted to how acne may present and be managed in individuals with skin of color (i.e., the broad and diverse range of populations that self-identify as belonging to a non-White racial/ethnic group and share characteristics such as higher skin phototypes and propensity toward hyperpigmentation). This review seeks to highlight aspects of acne that may be unique to skin of color.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 9","pages":"16-22"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11386966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Why Does Pigmented Purpuric Dermatosis Result in Residual Pigmentation in Contrast to Senile Purpura?","authors":"Yasuhiro Horiuchi","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 9","pages":"14-15"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11386969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Update on Prurigo Nodularis in Skin of Color.","authors":"Archana M Sangha","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 9-10 Suppl 1","pages":"S28-S29"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of GLP-1 Agonists in the Management of Cutaneous Disease.","authors":"Karan Lal, Emilee Herringshaw","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Glucagon-like peptide-1 (GLP-1) agonists are a class of medications indicated for type 2 diabetes and obesity that may play a role in the management of cutaneous disease, in part due to their anti-inflammatory effects. These molecules interact with cytokines critical to the development and persistence of skin disease, such as TNF-α, IL-23, IL-17 and IL-22. Correspondingly, immunologic pathways that are downregulated by GLP-1 agonists may serve as a target for various skin conditions that are worsened by inflammation. Furthermore, the known benefit of weight loss for certain skin conditions may be further potentiated by GLP-1 agonists. In this brief report, the authors describe multiple cases of patients with psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease for which patients experienced improvement subsequent to treatment with GLP-1 therapy. These cases demonstrate the utility of GLP-1 agonists in treating dermatologic conditions that are refractory to other therapies and further highlight the potential of GLP-1 agonists in treating skin disease.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 9","pages":"34-37"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11386968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Trichloroacetic Acid Peels in the Treatment of Melasma: A Split-face, Randomized, Prospective Trial in Latin American Women.","authors":"Deyson Lorenzo-Ríos, Gabriel Arias Berrios, Grecia I Cruz Goytía, Sofía Laguna Rocafort, Cristina N Brau Javier","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>There is controversy on the efficacy and safety of chemical peels used to treat Hispanic women with melasma. Studies evaluating superficial peels for melasma are limited due to lack of controls, blinding or objective assessment tools, poor inclusion of darker phototypes, and small sample number.</p><p><strong>Objectives: </strong>We sought to evaluate the safety and efficacy of trichloroacetic acid (TCA) peels when added to hydroquinone and tretinoin in the treatment of melasma in Hispanic women.</p><p><strong>Methods: </strong>A single blinded, prospective, split-face trial of superficial TCA peels was performed on Hispanic women with melasma. Topical hydroquinone and tretinoin were used on both sides. A total of four monthly peels were performed on one side. The relative reduction of melasma severity was evaluated using narrowband reflectance spectrophotometry (NRS), Modified Melasma Area and Severity Index (mMASI), and Global Melasma Severity Assessment (GMSA). Adverse events were monitored.</p><p><strong>Results: </strong>Thirty-three patients completed the study. Pigment intensity was reduced on both sides based on all measures. A greater improvement of mMASI and GMSA was achieved on the peeled side.</p><p><strong>Limitations: </strong>Limitations include the single-center study design with one blinded investigator.</p><p><strong>Conclusion: </strong>Based on our results, TCA peels appear to be safe and effective in augmenting treatment response on melasma patients with phototypes III and IV treated with hydroquinone and tretinoin.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 9","pages":"28-32"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11386972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}